Tag: RAD51D

ICARE Newsletter Fall 2023

Recommendations for Inherited Ovarian Cancer Genes: United Kingdom (UK)

Through consensus, management recommendations were developed in the UK for females with pathogenic variants inthe following inherited ovarian cancer genes: RAD51C, RAD51D, BRIP1, and PALB2. Hanson, et al. J Med Genet. 2023;60(5):417-429. PMID: 36411032. Social media post September 26th, 2023.Available at https://tinyurl.com/post9262023.

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-recommendations-for-inherited-ovarian-cancer-genes-united-kingdom-uk/

ICARE Social Media Post October 2023

What Are Established Cancer Genes?

There are many different inherited breast cancer genes, and different genes lead to different levels of breast cancer risk:

Permanent link to this article: https://inheritedcancer.net/post100423/

ICARE Social Media Post August 2023

UK Recommendations for: Inherited Ovarian Cancer Genes

Through consensus, management recommendations were developed in the UK for females with pathogenic variants in the following inherited ovarian cancer genes: Learn more at the link in bio! Reference: Hanson H, et al. J Med Genet. 2023;60(5):417-429. PMID: 36411032.

Permanent link to this article: https://inheritedcancer.net/post81823/

ICARE Social Media Post March 2023

BGREAT December 2022 Newsletter

Check out the latest edition of our B-GREAT newsletter for updates about inherited cancers in the context of racial inequalities in healthcare. You can read the newsletter by visiting 👇https://bgreatinitiative.inheritedcancer.net/wp-content/uploads/BGREAT-December-2022-Newsletter.pdf Please feel free to share with family members, friends, and/or your healthcare providers.

Permanent link to this article: https://inheritedcancer.net/post30623/

ICARE Newsletter Spring 2022 

 Ask the Expert 

The below question was addressed by ICARE Founder, Dr. Tuya Pal, and her oncology colleague, Dr. Sonya Reid. Dr. Pal is a Professor of Genetic Medicine, Ingram Professor of Cancer Research, and the Associate Director for Cancer Health Disparities at VanderbiltIngram Cancer Center. Dr. Reid is an Assistant Professor of Hematology/Oncology at Vanderbilt University Medical …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-ask-the-expert/

ICARE Newsletter Fall 2022 

 Which Genes Are Confirmed as ‘Inherited Breast Cancer Genes’? 

There were two large studies published early last year that evaluated which genes raise risks for breast cancer, including breast cancer patients from many centers worldwide, representing the largest available datasets to look at this question. These efforts were led by the worldwide Breast Cancer Association Consortium (BCAC)1 and the United States-based CARRIERS consortium. The …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-which-genes-are-confirmed-as-inherited-breast-cancer-genes/

ICARE Newsletter Fall 2021 

Ask the Expert 


In each newsletter, we give participants the opportunity to have their questions addressed by experts in thefield. This question was addressed by Kerry Schaffer, MD, medical oncologist at Vanderbilt University MedicalCenter with a focus on urological cancers. Q. Is there enough information to consider using PARP inhibitors to treat inherited forms ofprostate cancer? A. Over …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-ask-the-expert/

Newsletter Fall 2021

Inherited Cancer Treatment Updates

Early-stage, high-risk breast cancer in BRCA carriers: Results of the highly awaited phase 3 OlympiA trial showed promising results for EARLY STAGE (i.e., localized Stage 2-3) high-risk breast cancer patients with a BRCA mutation who were treated with a PARP inhibitor (olaparib) in the adjuvant setting (i.e., AFTER surgery).1 Early-stage breast cancer in this trial …

Continue reading

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-inherited-cancer-treatment-updates/

ICARE Social Media Post May 2022

Breast Cancer Genes in Women of African Ancestry

A recent study in women of African ancestry confirmed genes previously identified to have associations with breast cancer risk (BRCA1, BRCA2, PALB2, ATM, TP53, NF1, and CHEK2) and provided new evidence of breast cancer risk for RAD51C and RAD51D, which was identified previously in European ancestry populations.Check out the full article at 👇https://pubmed.ncbi.nlm.nih.gov/35396981/Reference: DĂ­az-Zabala, et …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post51722/

ICARE Social Media Post February 2022

Breast Cancer Characteristics Across Genes


A new study demonstrated that breast cancer pathology and other clinical features differ by inherited breast cancer gene. Read the full article to learn more!https://jamanetwork.com/journals/jamaoncology/fullarticle/2788577Reference: Breast Cancer Association Consortium. JAMA Oncol. 2022 Jan 27. PMID: 35084436

Permanent link to this article: https://inheritedcancer.net/post20122/

ICARE Social Media Post August 2021

Metastatic Breast Cancer Genes

For additional information, read the Journal of Clinical Oncology article at the link below 👇 https://ascopubs.org/doi/10.1200/JCO.20.01200

Permanent link to this article: https://inheritedcancer.net/post82021/

ICARE Social Media Post July 2021

RAD51C & RAD51D Response to Rucaparib in Ovarian Cancer

Check out the Nature Communications article for more information: https://www.nature.com/articles/s41467-021-22582-6

Permanent link to this article: https://inheritedcancer.net/post70921/

ICARE Social Media Post June 2021

A Population-Based Study of Genes Previously Implicated in Breast Cancer

For additional information, read the article at the following link: https://www.nejm.org/doi/10.1056/NEJMoa2005936

Permanent link to this article: https://inheritedcancer.net/post62521/

ICARE Social Media Post March 2021

Three Articles: Breast Cancer Risks

For additional information about the: 》US-based study, visit: https://www.nejm.org/doi/full/10.1056/nejmoa2005936 》International study, visit: https://www.nejm.org/doi/full/10.1056/nejmoa1913948 》Accompanying editorial: https://www.nejm.org/doi/full/10.1056/NEJMe2035083

Permanent link to this article: https://inheritedcancer.net/post30921/

ICARE Newsletter Winter 2021

Inherited Breast Cancer Genes: Two New Important Articles Just Released

Results of a United States (U.S.)-based study1 and an international study2 were released in January in the New England Journal of Medicine and provide a much clearer picture about the role of inherited breast cancer genes in women without a family history of cancer, and how common these genes may be in the general population. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nlw2021/

ICARE Newsletter Winter 2021

Updates to National Comprehensive Cancer Network (NCCN) Guidelines Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

Released September 8th, 2020: Genetic testing criteria by cancer type: Breast Cancer: Broadened to include relatives with ALL grades of prostate cancer (not just high-grade) Having multiple breast cancer diagnoses no longer depends on whether the diagnoses were on two different breasts Prostate Cancer: Now includes cribriform histology and ANY risk group (not just high-grade …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nlw2021/

ICARE Featured Video September & October 2020

NCCN Genetic/Familial Breast, Ovarian, and Pancreatic Guidelines

Below you may watch a featured video from the September 2020 and October 2020 Genetics Case Conference, which outlined updates to the National Comprehensive Cancer Network (NCCN) guidelines. Check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/video100820/

ICARE Social Media Post September 2020

NCCN Breast Cancer Risk Management Updates by Gene

The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020, which included updates to breast cancer risk management recommendations by gene as follows:  NBN – high-risk breast screening was removed as there is insufficient evidence to support high cancer risks BARD1 – added consideration for high-risk breast screening starting at age 40  …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post91020/

ICARE Newsletter Winter 2018

The Role of “Non-Truncating” Mutations in RAD51D on Ovarian Cancer Risk

As testing has broadened to include newer inherited cancer genes, studies have suggested that mutations which shorten the protein (“truncating mutations”) in the RAD51D gene are associated with ovarian cancer.  However, a recent study examined ovarian cancer risks for a “non-truncating” change (a single base pair within the gene is changed which is called a …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nlw2018/

ICARE Newsletter Summer 2017

Breast and Ovarian Cancer Associations for Genes Tested Through Multi-Gene Panels

As testing for multiple genes at the same time (“multi-gene panel testing”) has become increasingly available with tremendous advances in genetic testing technology, it has become critical to evaluate and refine cancer associations and levels of risk for many of these genes now tested. Through a commercial laboratory database of almost 100,000 results of multi-gene …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nls2017/

ICARE Newsletter Summer 2016

Practice Guideline Updates for NCCN Genetic/Familial High-Risk Assessment

The National Comprehensive Cancer Network (NCCN) is a network of oncology healthcare providers who work together to develop best practice guidelines for the delivery of cancer care. Given the increasing use of testing for mutations in several inherited cancer genes at one time (called “multi-gene panel testing”), the Breast/Ovarian and Colorectal Panels sought to provide …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nls2016/

ICARE Newsletter Summer 2016

An Approach to Making Risk Management Recommendations for Newer Inherited Cancer Genes

A recent article sought to develop an approach to cancer risk management among individuals with mutations in newer inherited cancer genes, many of which result in a moderate (rather than ‘high’) cancer risk. Overall, the investigators suggest a framework that takes the age-specific, lifetime, and absolute cancer risks into account for inherited cancer genes where …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nls2016/

ICARE Newsletter Winter 2016

What Is the Risk for Ovarian Cancer Among Women with Mutations in Newer Ovarian Cancer Genes?

The most common form of inherited ovarian cancer is due to mutations in the BRCA1 and BRCA2 genes, which are present in 10-15% of women with ovarian cancer and lead to an ovarian cancer risk of up to 44% and 27%, respectively.  Another set of genes known to raise ovarian cancer risks are the mismatch …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nlw2016/

ICARE Newsletter Summer 2015

2015 NCCN Clinical Practice Guideline Update

Breast and Ovarian Management Based on Genetic Test Resultsa   Recommend Breast MRIc (>20% lifetime risk of breast cancerd) Recommend Risk-reducing salpingo-oophorectomy Discuss Option of Risk-reducing mastectomy Intervention warranted based on gene and/or risk level ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11, TP53 BRCA1, BRCA2, Lynch syndromee BRCA1, BRCA2, CDH1, PTEN, TP53 Insufficient evidence …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nls2015/